Who are Norepinephrine intra-arteriel/hepatic's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epinephrine Injection, Norepinephrine (static group), Norepinephrine (dynamic group), Experimental dosing of labetalol, norepinephrine+vasopressin, labetalol intravenous.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norepinephrine-intra-arteriel-hepatic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Norepinephrine intra-arteriel/hepatic — Competitive Intelligence Brief

Norepinephrine intra-arteriel/hepatic (Norepinephrine intra-arteriel/hepatic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine / Adrenergic agonist. Area: Hepatology / Critical Care.

marketed Sympathomimetic amine / Adrenergic agonist Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor Hepatology / Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Norepinephrine intra-arteriel/hepatic (Norepinephrine intra-arteriel/hepatic) — University Health Network, Toronto. Norepinephrine administered directly into the hepatic artery increases vasoconstriction and blood pressure locally to reduce bleeding from esophageal varices.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Norepinephrine intra-arteriel/hepatic TARGET	Norepinephrine intra-arteriel/hepatic	University Health Network, Toronto	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
Epinephrine Injection	Epinephrine Injection	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	marketed	Catecholamine; alpha and beta adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Norepinephrine (static group)	Norepinephrine (static group)	Algemeen Ziekenhuis Maria Middelares	marketed	Catecholamine vasopressor	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
Norepinephrine (dynamic group)	Norepinephrine (dynamic group)	Algemeen Ziekenhuis Maria Middelares	marketed	Catecholamine vasopressor	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
Experimental dosing of labetalol	Experimental dosing of labetalol	Albany Medical College	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
norepinephrine+vasopressin	norepinephrine+vasopressin	Peking Union Medical College Hospital	marketed	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor
labetalol intravenous	labetalol intravenous	Haseki Training and Research Hospital	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine / Adrenergic agonist class)

Al-Azhar University · 1 drug in this class
Amphastar Pharmaceuticals, Inc. · 1 drug in this class
Oman Medical Speciality Board · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norepinephrine intra-arteriel/hepatic — Competitive Intelligence Brief. https://druglandscape.com/ci/norepinephrine-intra-arteriel-hepatic. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab